Mid-term effects of lung volume reduction surgery on pulmonary function in patients with chronic obstructive pulmonary disease.

BACKGROUND: Now lung volume reduction surgery (LVRS) has become one of the most effective methods for the management of some cases of severe chronic obstructive pulmonary disease (COPD). We evaluated the mid-term effects of LVRS on pulmonary function in patients with severe COPD. METHODS: Ten male patients with severe COPD aged 38 - 70 years underwent LVRS and their pulmonary function was assessed before, 3 months and 3 years after surgery. The spirometric and gas exchange parameters included residual volume, total lung capacity, inspiratory capacity, forced vital capacity, forced expiratory volume in one second, diffusion capacity for CO, and arterial blood gas. A 6-minute walk distance (6MWD) test was performed. RESULTS: As to preoperative assessment, most spirometric parameters and 6MWD were significantly improved after 3 months and slightly 3 years after LVRS. Gas exchange parameters were significantly improved 3 months after surgery, but returned to the preoperative levels after 3 years. CONCLUSIONS: LVRS may significantly improve pulmonary function in patients with severe COPD indicating for LVRS. Mid-term pulmonary function 3 years after surgery can be decreased to the level at 3 months after surgery. Three years after LVRS, lung volume and pulmonary ventilation function can be significantly improved, but the improvement in gas exchange function was not significant.

[Effect of lung transplantation on pulmonary function in 5 patients with chronic obstructive pulmonary disease].

OBJECTIVE: To investigate the therapeutic effect of lung transplantation on pathophysiology and pulmonary function in chronic obstructive pulmonary disease (COPD) patients. METHODS: Five male COPD (grade IV) patients, aged 51 to 63 yr, were enrolled in the study. The patients underwent pulmonary function tests and the following measurements 2 weeks before and 2 months after the operation. The measured parameters included forced vital capacity (FVC), forced expiratory volume in one second (FEV(1)), FEV(1)/FVC, maximal ventilatory volume (MVV), residual volume (RV), total lung capacity (TLC), RV/TLC, inspiratory capacity (IC), thoracic gas volume (TGV), peak expiratory flow (PEF), total airway resistance (R(aw)total), diffusion capacity for CO of lung (D(L)CO), diffusion capacity for CO of lung/alveolar volume (D(L)CO/V(A)), 6 minute walk distance (6MWD), partial pressure of oxygen in arterial blood (PaO(2)), alveolar-artery oxygen gradient [P((A-a))O(2)], oxygen saturation in arterial blood (SaO(2)), partial pressure of carbon dioxide in arterial blood (PaCO(2)) and mean pulmonary arterial pressure (mPAP). RESULTS: The measured parameters before vs after the operation were as follows: MVV (23.6 +/- 5.8) vs (71.6 +/- 21.8) L, FEV(1) (0.68 +/- 0.21) vs (1.85 +/- 0.46) L, FEV(1)/FVC (37.4 +/- 8.3)% vs (75.6 +/- 13.9)%, PaO(2) (60.0 +/- 9.1) vs (86.2 +/- 2.9) mm Hg (1 mm Hg = 0.133 kPa), SaO(2) (90.0 +/- 4.6)% vs (96.8 +/- 0.5)% and mPAP (31.2 +/- 5.5) vs (16.6 +/- 1.8) mm Hg; all were significantly improved in the 5 cases (all P < 0.05); IC [(1.16 +/- 0.26) vs (1.83 +/- 0.35) L], TGV [(6.52 +/- 0.27) vs (4.52 +/- 0.29) L], RV [(5.12 +/- 0.39) vs (3.20 +/- 0.32) L], RV/TLC [(71.0 +/- 5.6)% vs (51.3 +/- 2.5)%] and R(aw) total [(6.62 +/- 0.99) vs (2.48 +/- 0.87) cm H2O.L(-1).s(-1)] were significantly improved in 3 of the 5 patients (all P < 0.05); PEF [(1.65 +/- 0.40) vs (3.92 +/- 1.63) L/s], D(L)CO [(8.5 +/- 3.0) vs (21.0 +/- 6.2) ml.min(-1).mm Hg(-1)] and 6MWD [(46.8 +/- 14.7) vs (246.8 +/- 51.9) m] were significantly increased in 4 of the 5 patients (all P < 0.05). FVC [(1.85 +/- 0.40) vs (2.45 +/- 0.49) L], TLC [(7.19 +/- 0.15) vs (6.26 +/- 0.73) L], D(L)CO/V(A) [(2.90 +/- 1.50) vs (5.41 +/- 0.87) L.min(-1).mm Hg(-1)], P((A-a))O(2) [(37.6 +/- 16.3) vs (17.8 +/- 6.3) mm Hg] and PaCO(2) [(44.6 +/- 7.7) vs (37.4 +/- 3.4) mm Hg] were also improved but did not reach significance (all P > 0.05). CONCLUSION: Spirometry, airway resistance, residual capacity, diffusion capacity, exercise tolerance and gas exchange were improved remarkably after lung transplantation in COPD patients.

Pulmonary sparganosis mansoni: a case report from a non-endemic region.

Sparganosis mansoni is a parasitic disease caused by the larva of Spirometra mansoni. It occurs worldwide, but only a few patients show pulmonary involvement. Here, we present a case of pulmonary sparganosis mansoni in a non-endemic region. A 32-year-old Chinese woman presented with intermittent bloody phlegm, peripheral blood eosinophilia, and migratory patch shadows in both lungs. She had been misdiagnosed with eosinophilic pneumonia. She had a history of eating raw frogs, and the sparganum mansoni antibody was positive in both her blood and bronchoalveolar lavage fluid. Several sparganum mansoni were found in a frog sample that the patient provided. Consequently, she was diagnosed with pulmonary sparganosis mansoni. After two oral courses of praziquantel were administered, her symptoms and radiological lesions improved significantly. To our knowledge, this is the first case of pulmonary sparganosis mansoni occuring in Shanghai. Oral praziquantel is effective for the treatment of sparganosis mansoni, although its course of therapy may need to be repeated.